// App-Quantinova.ai

EP981 : ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH HIGH-RISK CYTOGENETICS: IKEMA SUBGROUP ANALYSIS

Researchers

Presenter

  • Ivan Spicka

Principal Investigators

  • Philippe Moreau

  • Thomas Martin

  • Thierry Facon

  • Gracia Martinez

  • Albert Oriol

  • Youngil Koh

  • Andrew Lim

  • Gabor Mikala

  • Laura Rosiol

  • Mnci Yagci

  • Michele Cavo

  • Marie-Laure Risse

  • Galle Asset

  • Sandrine Mac

  • Helgi van de Velde

  • Kwee Yong

Medical Centers

  • University of California, San Francisco, San Francisco, California, United States

  • Department of Hematology and Stem Cell Transplantation,National Institute for Hematology and Infectious Diseases, South Pest Central Hospital,Budapest,Hungary

  • Universite Nantes, Nantes, France

  • Austin &amp

  • Sanofi R&amp

  • Clinical Department of Haematology, 1st Medical Department, Charles University in Prague, Prague, Czech Republic

  • Department of Biology, Lille University Hospital, Lille, France

  • Hematology Department,Institut Català d’Oncologia and Josep Carreras Institute, Hospital Germans Trias i Pujol,Barcelona,Spain

  • Vitry-Sur-Seine, France

  • Seragnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy

  • Austin & Repatriation Medical Center, Heidelberg, Victoria, Australia

  • D,Chilly-Mazarin,France

  • Sanofi, Cambridge, United States

  • Hospital das Clínicas—University of São Paulo, São Paulo, Brazil

  • Hospital Clinic, IDIBAPS, Barcelona, Spain

  • Chonbuk National University Medical School, Jeonju, Korea, Republic of

  • Department of Medical Oncology, University College London Hospital, London, United Kingdom

  • Ankara University, Ankara, Turkey

Locations

  • United States

  • Hungary

  • France

  • Czech Republic

  • Spain

  • Italy

  • Australia

  • Brazil

  • Republic of South Korea

  • United Kingdom

  • Turkey

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • carfilzomib Intravenous

  • Isatuximab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT03275285

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved